China Pharmaceutical Sector Report 2024 Q4

According to Deloitte, China has been the second largest pharmaceutical market after the US since 2017 and had a market share of 11% in the global pharmaceutical market by the end of 2022. According to the National Bureau of Statistics (NBS), the total revenue of China's pharmaceutical firms above designated size (annual revenue above RMB 20mn) dropped by 3.7% y/y in 2023, mainly impacted by the relaxation of pandemic-related controls, as well as by the centralised procurement which lowered the selling prices of many drugs. With respect to active pharmaceutical ingredients (APIs), in 2023, due to the dropping sales to Europe and the US, China's export value of APIs dropped by 20.7% y/y to USD 40.9bn, while the export volume of APIs reached 12.5mn tonnes, achieving a 5.4% y/y increase.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in China
• Crystallise the forces both driving and restraining this sector in China
• Ascertain China’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in China.
• Build a clear picture of trends, output and consumption for specific sub-sectors